English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

HYPERTENSION AND EDEMA RATES IN 6,717 PATIENTS FOR THE NEW COX-2 INHIBITOR, VALDECOXIB VERSUS THE CONVENTIONAL, NONSELECTIVE NSAIDS AND PLACEBO Andrew Whelton, William B White, Jeffrey D Kent, Kenneth M Verburg. University Clinical Research Center Inc, and Johns Hopkins Medical School, Baltimore, MD; Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT; Department of Clinical Research, Pharmacia Corporation, Skokie, IL.

Hypertension and edema rates in 6,717 patients for the new COX-2 inhibitor, valdecoxib versus the conventional, nonselective NSAIDs and placebo